This site is intended for Healthcare professionals only.

AstraZeneca wins UK cost approval for longer use of heart drug


AstraZeneca wins UK cost approval for longer use of heart drug

Long term use of AstraZeneca’s blood thinner Brilinta has been recommended as a cost-effective option for treating patients after a heart attack, Britain’s healthcare cost watchdog NICE said.

Ticagrelor 60 mg sold in Britain as Brilique for just under 1 pound ($1.30) a pill could help “many thousands of people” when given twice a day alongside aspirin, the National Institute for Health and Care Excellence (NICE) said.

In the United States, the wholesale acquisition cost is $5.14 a pill, although most U.S. patients are eligible for savings programs.

A higher 90 mg dose of Brilique is already recommended for 12 months after a heart attack. Now new NICE draft guidance supports continued use at a lower dose for a further three years to reduce the risk of fresh heart attacks or strokes.

The drug is an important driver of future sales for AstraZeneca, which believes it can eventually sell $3.5 billion a year. Global sales in the first half of 2016 were $395 million.

The low-dose version of the medicine was recommended for long-term use by the U.S. Food and Drug Administration in September 2015 and by European authorities in February 2016.



Source: Reuters
0 comment(s) on AstraZeneca wins UK cost approval for longer use of heart drug

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted